论文部分内容阅读
本文报道了IMB-86001的体外、体内抗菌活性,并与其它喹诺酮类药物进行了比效。实验结果表明:IMB-86001是一个广谱、强效喹诺酮类抗菌药,对革兰氏阳性(G~+)菌的MIC为0.09～6.25μg/ml对革兰氏阴性(G~-)菌的MIC为0.011～0.78μg/ml,对611株临床分离菌的抗菌活性略逊于环丙氟哌酸(CPFLX),但比氟啶酸(ENX)、氟哌酸(NFLX)和吡哌酸(PPA)的活性强。杀菌实验表明:IMB-86001对金葡菌、大肠杆菌菌和绿脓杆菌为杀菌作用。其抗菌活性随菌量增多而略下降,抗菌活性在偏硷性时较强,血清对其抗菌活性无明显影响。IMB-86001在体内效果(ED_(50))明显优于ENX、NFLX和PPA,也略优于CPFLX。
In this paper, the antibacterial activity of IMB-86001 in vitro and in vivo was reported and compared with other quinolones. The results showed that IMB-86001 is a broad-spectrum and potent quinolone antibacterial agent against Gram-positive (G ~ +) bacteria with a MIC of 0.09 ~ 6.25μg / ml against Gram-negative The antibacterial activity of 611 clinical isolates was slightly lower than that of ciprofloxacin (CPFLX) but lower than that of ENF, NFLX, and pipemidic acid (PPA) activity. Bactericidal experiments show that: IMB-86001 against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa for bactericidal effect. The antibacterial activity slightly decreased with the increase of the amount of bacteria. The antibacterial activity was stronger in the alkalinity and the serum had no obvious effect on the antibacterial activity. IMB-86001 in vivo effect (ED_ (50)) was significantly better than ENX, NFLX and PPA, but also slightly better than CPFLX.